Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow Health (NASDAQ: HROW) announced the completion of a private sale of 440,000 shares of Series B Cumulative Preferred Stock, raising approximately $10.67 million. The funds will support general corporate purposes, including strategic product acquisitions and working capital. CEO Mark L. Baum highlighted that this transaction, along with previous fund raises totaling over $75 million in 2021, strengthens the company’s financial position for pursuing FDA-approved ophthalmic drug candidates. Harrow's focus remains on growth in the ophthalmic healthcare sector.
Harrow Health, Inc. (NASDAQ: HROW) announced the closing of an additional $5 million in 8.625% senior notes due 2026, following the exercise of the underwriters’ option from a previous $50 million offering. The total gross proceeds from this issuance amount to $55 million before fees. The additional notes will trade under the symbol HROWL. Funds will be allocated for general corporate purposes, including product acquisitions and capital expenditures. Both the notes and additional notes received a 'BB' rating from Egan-Jones Ratings Company.
Harrow Health, Inc. (NASDAQ: HROW) will announce its Q1 2021 financial results on May 11, 2021, after market close. The company specializes in ophthalmology and will provide a business update during a conference call at 4:45 p.m. ET on the same day. Investors can access the call details and results on the company’s website. Harrow Health owns ImprimisRx and Visionology, and holds substantial equity in Eton Pharmaceuticals and others. For more details, visit harrowinc.com.
Harrow Health (NASDAQ: HROW) has successfully closed a public offering of $50 million in senior notes, yielding approximately $48 million in net proceeds. The 8.625% senior notes, due in 2026, are set to trade on Nasdaq under the symbol 'HROWL'. Funds will primarily be used to repay $15.5 million of existing debt, with remaining proceeds allocated for general corporate purposes, including strategic acquisitions and working capital. The offering was rated 'BB' by Egan-Jones Ratings Company, enhancing investor confidence.
Harrow Health, an ophthalmic healthcare company, announced a public offering of $50 million in senior notes with an interest rate of 8.625%, due in 2026. The offering is expected to close on April 20, 2021, with a potential additional $5 million from underwriters. Proceeds will be used to repay $15.5 million in existing borrowings and fund general corporate purposes, including strategic acquisitions. The notes, rated 'BB,' will be listed on Nasdaq under the symbol 'HROWL.' The offering follows the company's SEC-approved shelf registration statement.
Harrow Health, Inc. (NASDAQ: HROW) has launched a public offering of $25 million in senior notes due 2026, pending market conditions. The notes received a "BB" rating from Egan-Jones Ratings Company. Proceeds are intended to repay $15.5 million of outstanding borrowings under a term loan and for general corporate purposes including strategic acquisitions and working capital. The offering is made under an effective SEC registration statement. B. Riley Securities and others are managing the offering.
Harrow Health, Inc. (NASDAQ: HROW) reported preliminary unaudited financial results for Q1 2021, estimating total revenue between $14.9 million and $15.5 million with an Adjusted EBITDA exceeding $2.7 million. As of March 31, 2021, the company had approximately $6.5 million in cash and cash equivalents, which increased by $10.6 million from the sale of shares in Eton Pharmaceuticals. The final results will be announced on May 11, 2021.
Harrow Health (NASDAQ: HROW) reported a strong fourth quarter of 2020 with revenues of $14.6 million, marking a 16% increase from $12.6 million in the previous year. Adjusted EBITDA hit a record $4.0 million, up from $2.1 million year-over-year. Operating income rose to $2.6 million compared to $0.9 million in Q4 2019, while gross margins remained stable at 73%. The increase in revenue was attributed in part to $349,000 in Dexycu® commissions. CEO Mark L. Baum noted the company's resilience amid challenges and expressed optimism about future growth.
Harrow Health, Inc. (NASDAQ: HROW) announced participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Mark Baum and CFO Andrew Boll will engage in a virtual presentation available on the company's investor relations site starting March 9, 2021, at 7:00 a.m. ET, archived for 90 days. The management team will also hold one-on-one meetings via H.C. Wainwright. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leader in ophthalmology outsourcing and pharmaceutical compounding.
Harrow Health, Inc. (NASDAQ: HROW) announced it will release its fourth quarter and annual financial results for the year ending December 31, 2020, on March 8, 2021, after the market close. The financial results will be available on their website, and a conference call will occur at 4:45 p.m. ET to discuss the outcomes and present a business update. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leading ophthalmology outsourcing business.